Caffeinism Associated With Greater Use of Other Psychotropic Agents

John F. Greden, Andrew Procter, and Bruce Victor

CAFFEINISM, a diagnosis recently included in the third edition of the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM-III), is characterized by a constellation of affective, sleep, and psychophysiological manifestations. Because symptoms of caffeineism might be confounded or masked by simultaneous ingestion of other drugs, it is pertinent to ask whether high consumers of caffeine differ from low or moderate consumers in their use of other psychoactive agents. Few data are currently available to answer this question.

Historically, 18th-century physicians suggested that tea and coffee consumption promoted later use of alcohol, opium, and other stimulants. Such claims were never proven. In contrast, increased cigarette smoking has been conclusively associated with high caffeine consumption. Although Greden et al. noted that a greater proportion of high caffeine consumers reported use of minor tranquilizers when compared with low or moderate caffeine users, few or no studies have described patterns of use for hypnotics, neuroleptics, antidepressants, or lithium among subgroups of caffeine users.

The importance of documenting possible interactions between use of caffeine and use of other drugs increased with several recent discoveries. First, caffeine was shown to interact in vitro with a number of neuroleptics to form flaky precipitates and thus possibly impair the efficacy of these agents. Second, caffeine clinically antagonizes barbiturates and monoamine oxidase inhibitors (MAOI). Third, caffeine and caffeine withdrawal have been noted to alter adrenergic and serotonergic transmission, and thus may interfere with expected results from common psychiatric medications. Finally, following the exciting discovery that the brain contained specific receptors for benzodiazepines, it was noted that caffeine was a competitive inhibitor of diazepam binding to these brain receptors. Conceivably, competitive interference

From the University of Michigan Medical Center, Ann Arbor, Mich., and Langley Porter Hospital, San Francisco, Calif.

John F. Greden, M.D.: Professor of Psychiatry, Director, Clinical Studies Unit, Scientific Associate, Mental Health Research Institute, Department of Psychiatry, University of Michigan Medical Center, Ann Arbor, Mich.; Andrew Procter: Medical Student, Guy's Hospital Medical School, London, England; Bruce Victor, M.D., Department of Psychiatry, Langley Porter Hospital, San Francisco, Calif.

Supported in part by the Mental Health Research Institute, Department of Psychiatry, University of Michigan Medical Center, Ann Arbor, Mich.

Address reprint requests to John F. Greden, M.D., Department of Psychiatry, University of Michigan Medical Center, Ann Arbor, Mich. 48109.

© 1981 by Grune & Stratton, Inc. 0010-440X/81/2206-0005$01.00/0

Comprehensive Psychiatry, Vol. 22, No. 6 (November/December), 1981 565
with endogenous benzodiazepine ligands might even explain caffeine’s stimulant, anxiety-like actions.

To assess whether use of other psychoactive agents differed among caffeine using subgroups, we studied 205 hospitalized patients and compared three subgroups of caffeine users. We observed that: (1) low, moderate and high caffeine-consuming subgroups differed in their use of other psychoactive substances, specifically tobacco, minor tranquilizers, and sedative-hypnotics; (2) similar patterns of associated psychotropic drug use were found among psychiatric and nonpsychiatric patients, although amounts were greater in psychiatric patients; and (3) caffeine-using subgroups did not differ in their use of neuroleptics, antidepressants, lithium, or stimulants. This article describes these results in detail.

MATERIALS AND METHODS

Data Collection

A 220-item questionnaire was administered to 205 hospitalized patients at the University of Michigan Medical Center. As described more extensively in earlier publications,7,13,16 the questionnaire consisted of an informed consent form, demographic information, and 190 keypunchable items. The form determined total caffeine intake by summing caffeine ingestion from all common sources, including tea, coffee, cola drinks, and 25 caffeine-containing medications. We assessed other psychoactive drug use by inquiring about frequency and quantity of each subject’s intake of tobacco, minor tranquilizers (benzodiazepines or meprobamate), neuroleptics, antidepressants, sedative-hypnotics, lithium, and stimulants. To enhance response accuracy, common pharmaceutical brand names were included in the questionnaire (e.g., Valium, Thorazine, Secanol). We emphasize that we assessed use of caffeine and other drugs prior to hospitalization. The questionnaire had been previously pilot tested, validated by interview, and employed in other studies.7,13,16

Subjects

Respondents included 81 hospitalized psychiatry patients, and 124 hospitalized nonpsychiatry patients. The latter were operationally defined as individuals who had never received treatment by a psychiatrist. They conceivably could have received psychotropic agents from nonpsychiatric physicians. Demographic characteristics of both subgroups are illustrated in Table 1. The two subgroups differed significantly in sexual distribution and marital status, but not in age, race, religion or educational level (p > 0.05). Neither sex nor marital status have been shown to significantly modify caffeine intake.7 Thus, we concluded that the two subgroups could be compared with each other. Furthermore, in this study we primarily sought to evaluate drug use among different caffeine consuming subgroups and studied nonpsychiatric patients mainly because many of the drugs we were assessing are commonly prescribed in psychiatric settings. If greater use of other psychoactive drugs were truly linked to caffeine use, such a pattern would need to be documented among nonpsychiatric as well as psychiatric patients.

DATA ANALYSIS

For purposes of comparing caffeine-using subgroups,7 we divided subjects into three categories depending upon their total caffeine intake. These included: (1) low consumers (0–249 mg per day); (2) moderate consumers (250–749 mg per day); and (3) high consumers (750 mg or more per day). Use of other psychotropic agents was then compared among these three subgroups. Chi square analysis was utilized, accepting p < 0.05 as indicating significance.
CAFFEINISM

Table 1. Demographic Characteristics of Psychiatric and Nonpsychiatric Groups, in Percentages

<table>
<thead>
<tr>
<th></th>
<th>Psychiatric (n = 81)</th>
<th>Nonpsychiatric (n = 124)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 25 years</td>
<td>31</td>
<td>20</td>
</tr>
<tr>
<td>26–40 years</td>
<td>34</td>
<td>36</td>
</tr>
<tr>
<td>41 and above</td>
<td>35</td>
<td>44</td>
</tr>
<tr>
<td>Sex*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>30</td>
<td>69</td>
</tr>
<tr>
<td>Male</td>
<td>70</td>
<td>31</td>
</tr>
<tr>
<td>Race†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-White</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>White</td>
<td>92</td>
<td>92</td>
</tr>
<tr>
<td>Marital Status*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonmarried</td>
<td>58</td>
<td>25</td>
</tr>
<tr>
<td>Married</td>
<td>42</td>
<td>75</td>
</tr>
<tr>
<td>Religion†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Catholic</td>
<td>32</td>
<td>33</td>
</tr>
<tr>
<td>Protestant</td>
<td>52</td>
<td>60</td>
</tr>
<tr>
<td>Other</td>
<td>16</td>
<td>17</td>
</tr>
<tr>
<td>Education†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; High School</td>
<td>36</td>
<td>31</td>
</tr>
<tr>
<td>High School</td>
<td>28</td>
<td>31</td>
</tr>
<tr>
<td>&gt; High School</td>
<td>36</td>
<td>38</td>
</tr>
</tbody>
</table>

* Chi square, p <0.001.
† Chi square, nonsignificant at 0.05 level.

RESULTS

Total Caffeine Use

When the total sample of 205 subjects was considered, 39.5% were low caffeine consumers, 42.5% were moderate consumers, and 18.0% ingested more than 750 mg caffeine per day, qualifying as high consumers. The psychiatric and nonpsychiatric subjects did not differ significantly in their caffeine use, although an observable trend was that 16% of the nonpsychiatric patients were high consumers, compared with 23% of the psychiatric patients.

Drug Use Among Caffeine-Consuming Subgroups in the Total Sample

Figure 1 illustrates reported use of other psychotropic drugs within the past month among the three caffeine-consuming subgroups. In the total sample of 205 subjects, as caffeine use increased from low to moderate to high we noted a corresponding increase in the percentage using cigarettes. Specifically, 69% of high caffeine consumers smoked tobacco, compared to only 31% of low caffeine users (chi square = p < 0.001). A greater percentage of high caffeine users also reported use of minor tranquilizers (benzodiazepines or meprobamate) within the past month, (chi square = p < 0.01). In contrast to these statistically-significant differences, use of stimulants, sedative hypnotics, major tranquilizers, antidepressants, and lithium failed to differ significantly among the three subgroups.
DRUG USE AMONG CAFFEINE-CONSUMING SUBGROUPS: PSYCHIATRIC VS. NONPSYCHIATRIC PATIENTS

To address the comparison between psychiatric and nonpsychiatric subjects, we focused upon the three drugs whose use differed most significantly in association with caffeine use, i.e., cigarettes, minor tranquilizers, and sedative-hypnotics. The use of these three agents was greater in all caffeine-using subgroups among psychiatric patients when compared with nonpsychiatric subjects (Fig. 2). Stated differently, low caffeine-consuming psychiatric patients had more associated drug use than low caffeine-consuming nonpsychiatric patients, and similarly for moderate and high caffeine users. In both psychiatric and nonpsychiatric subgroups, however, the highest caffeine users generally also had the highest associated use of other psychoactive drugs, indicating this was not simply related to psychiatric patient status.

Eighty-two percent of psychiatric patients who ingested more than 750 mg caffeine per day also reported smoking, seventy-one percent used minor tranquilizers, and 53% reported recent use of sedative-hypnotics. The magnitude of these figures is noteworthy.

When we further analyzed frequency of drug use, specifically measuring "occasional" use (operationally defined in the questionnaire as once a week or less) or "regular" use (operationally defined as twice a week or more frequently), patterns identical to monthly use were found. In comparison to nonpsychiatric patients, more high caffeine-consuming psychiatric patients reported occasional and regular use of sedative-hypnotics, minor tranquilizers, and cigarettes. Forty-one percent of psychiatric high caffeine consumers reported regular use of minor tranquilizers and 24% regular use of sedative-hypnotics, compared to 15% and 5% of nonpsychiatric high caffeine users,
respectively. To reiterate, however, heaviest caffeine consumers—whether psychiatric or nonpsychiatric—had the highest use.

**DISCUSSION**

These data document for the first time that among high caffeine consumers, there is significantly greater use of selected other psychoactive drugs, whether individuals are psychiatric or nonpsychiatric patients. Most high caffeine consumers smoke extensively. The majority report recent use of benzodiazepines or meprobamate. Approximately half report recent use of sedative hypnotics. We suggest that these polydrug patterns have potential clinical implications.

Tobacco use, for example, has been shown to complicate prescribed psychiatric treatments, partially because nicotine activates the hepatic enzyme system and lowers plasma levels of neuroleptics and tricyclic antidepressants. High caffeine use may similarly interfere with the desired clinical effects of psychiatric medications by counteracting their desired effects or by formation of flaky precipitates and decreased absorption, as described previously. Since only combined caffeine and tobacco use has been shown to alter lipoprotein levels, it is also conceivable that combined use of these two drugs could produce psychiatric consequences not characteristic of either drug alone. Assessment of this possibility is indicated.

The finding that 65% of high caffeine users in the total sample reported use of minor tranquilizers within the past month has definite epidemiological significance. Several factors may contribute to this combined use. Heavy users, for example, might ingest minor tranquilizers in an attempt to counteract the toxic manifestations of high caffeine consumption. As previously reported, the clinical picture of a person with caffeinism may be so similar to patients with an anxiety state that there may be diagnostic confusion. Physicians might then prescribe benzodiazepines rather than recommend elimination of caffeine.
The neurobiological mechanism underlying this pattern is probably related to the fact that caffeine and endogenous benzodiazepine ligands compete with each other for the same brain receptor sites. Thus, it would be predictable that as caffeine use increased, receptor competition would also increase, interfering with the "tranquilizing" effects of endogenous benzodiazepine ligands and producing CNS excitation. The highest caffeine users might then seek to restore the balance by greater use of "exogenous" benzodiazepines, as observed in our study sample. This documented association raises important clinical concerns. If benzodiazepines are effective in minimizing symptoms of caffcinism, the manifestations of such a syndrome may be chronically masked by these drugs. The treatment of choice, in fact, ought to be reduction of caffeine intake, rather than adding an anxiolytic agent. Inversely, in cases when anxiety is due to other causes and benzodiazepines are appropriately prescribed, it seems likely that their efficacy might be reduced by excessive caffeine use, perhaps even when consumed in small quantities. This emphasizes the importance of asking patients about caffeine use. Certainly, in evaluating the claimed over-utilization of benzodiazepines, associated caffeine use should always be considered a confounding factor. Such consideration has been rare.

Our finding that 24% of high caffeine consuming psychiatric patients reported regular use (twice per week or more) of sedative hypnotics is noteworthy. Analogous to the reported use of benzodiazepines, an antagonistic interaction is suggested. These findings support earlier observations by Forrest et al. that caffeine use at bedtime counteracts sedative-hypnotics. Long-term use of sedative-hypnotics is clinically questionable in most patients, but in patients with caffcinism it would seem especially dubious.

In contrast to differences in use of tobacco, minor tranquilizers or sedative hypnotics, caffeine-consuming subgroups did not differ in their reported use of major tranquilizers, antidepressants, or lithium. This suggests that the use of these latter agents primarily reflects prescribing patterns among physicians rather than drug-seeking behaviors among caffeine users. Another possibility is that caffcinism does not as frequently mimic the conditions for which neuroleptics, antidepressants, and lithium usually are prescribed, in contrast to anxiety and sleep disturbances which commonly lead to prescription of minor tranquilizers or sedative-hypnotics.

Although highest caffeine consumers reported greatest use of other psychotropic agents, whether they were psychiatric or nonpsychiatric patients, such intake was clearly more among those receiving treatment for psychiatric problems. Cause and effect relationships cannot be inferred from our study design. We wonder whether this observed increase in use of other psychoactive agents among caffeine-consuming psychiatric patients is related to more frequent prescriptions of common treatments for spontaneously-occurring psychiatric problems, to relief-seeking from previously-occurring caffcinism, or perhaps even casually contributing to their current psychiatric status. Only longitudinal assessments will adequately answer these important questions.

Hundreds of millions of persons experience the pharmacological effects of caffeine each day and a number of psychiatric implications have been iden-
ified from such use. The drug induces a distinct clinical syndrome, i.e., caffeinism.\textsuperscript{5,16} It can modify the clinical manifestations of spontaneously-occurring affective disorders.\textsuperscript{19} It has been reported to precipitate or exacerbate psychoses.\textsuperscript{7,20,21} Intravenous use of the drug helps reverse Parkinsonian symptoms associated with neuroleptic use.\textsuperscript{22} Caffeine withdrawal syndromes are frequent.\textsuperscript{15,23} In addition to these previously-reported psychiatric effects, results from this study suggest that high caffeine use is associated with greater use of various psychotropic agents. Future evaluations of these polypharmacy patterns are required, because with the high prevalence of such combined use, the clinical implications are potentially enormous.

REFERENCES